652 related articles for article (PubMed ID: 17879753)
1. In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-beta-cyclodextrin.
Nie S; Fan X; Peng Y; Yang X; Wang C; Pan W
Arch Pharm Res; 2007 Aug; 30(8):991-1001. PubMed ID: 17879753
[TBL] [Abstract][Full Text] [Related]
2. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the complexes of furosemide with 2-hydroxypropyl-beta-cyclodextrin and sulfobutyl ether-7-beta-cyclodextrin.
Spamer E; Müller DG; Wessels PL; Venter JP
Eur J Pharm Sci; 2002 Sep; 16(4-5):247-53. PubMed ID: 12208454
[TBL] [Abstract][Full Text] [Related]
4. Effects of the Preparation Method on the Formation of True Nimodipine SBE-β-CD/HP-β-CD Inclusion Complexes and Their Dissolution Rates Enhancement.
Semcheddine F; Guissi Nel I; Liu X; Wu Z; Wang B
AAPS PharmSciTech; 2015 Jun; 16(3):704-15. PubMed ID: 25511809
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes.
Patel SG; Rajput SJ
AAPS PharmSciTech; 2009; 10(2):660-9. PubMed ID: 19459053
[TBL] [Abstract][Full Text] [Related]
6. Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies.
Sherje AP; Kulkarni V; Murahari M; Nayak UY; Bhat P; Suvarna V; Dravyakar B
Mol Pharm; 2017 Apr; 14(4):1231-1242. PubMed ID: 28248111
[TBL] [Abstract][Full Text] [Related]
7. Inclusion Complexes of Hydroxy Propyl-β-Cyclodextrin and Paliperidone: Preparation and Characterization.
Sherje A; Londhe V
Curr Drug Discov Technol; 2014; 11(4):271-8. PubMed ID: 25578059
[TBL] [Abstract][Full Text] [Related]
8. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-beta-cyclodextrin.
Liu J; Qiu L; Gao J; Jin Y
Int J Pharm; 2006 Apr; 312(1-2):137-43. PubMed ID: 16459034
[TBL] [Abstract][Full Text] [Related]
9. The physicochemical characteristics and bioavailability of indomethacin from beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, and hydroxypropyl-beta-cyclodextrin complexes.
Jambhekar S; Casella R; Maher T
Int J Pharm; 2004 Feb; 270(1-2):149-66. PubMed ID: 14726131
[TBL] [Abstract][Full Text] [Related]
10. Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrin.
Liu M; Cao W; Sun Y; He Z
Int J Pharm; 2014 Dec; 477(1-2):159-66. PubMed ID: 25455768
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
[TBL] [Abstract][Full Text] [Related]
12. Dissolution enhancement of cefdinir with hydroxypropyl-β-cyclodextrin.
Guo B; Zhong S; Li N; Li X; Yi J; Jin M
Drug Dev Ind Pharm; 2013 Nov; 39(11):1638-43. PubMed ID: 24087855
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluation of an amylobarbitone/hydroxypropyl-beta-cyclodextrin complex prepared by a freeze-drying method.
Fathy M; Sheha M
Pharmazie; 2000 Jul; 55(7):513-7. PubMed ID: 10944779
[TBL] [Abstract][Full Text] [Related]
14. Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects.
Lima BDS; Campos CA; da Silva Santos ACR; Santos VCN; Trindade GDGG; Shanmugam S; Pereira EWM; Marreto RN; Duarte MC; Almeida JRGDS; Quintans JSS; Quintans LJ; Araújo AAS
Food Chem Toxicol; 2019 Apr; 126():15-24. PubMed ID: 30738132
[TBL] [Abstract][Full Text] [Related]
15. A novel oral delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for poorly water-soluble drug: vinpocetine.
Lin C; Chen F; Ye T; Zhang L; Zhang W; Liu D; Xiong W; Yang X; Pan W
Int J Pharm; 2014 Apr; 465(1-2):90-6. PubMed ID: 24530388
[TBL] [Abstract][Full Text] [Related]
16. Improvement of solubility and oral bioavailability of 2-(N-cyanoimino)-5-[(E)-4-styrylbenzylidene]-4-oxothiazolidine (FPFS-410) with antidiabetic and lipid-lowering activities in dogs by 2-hydroxypropyl-beta-cyclodextrin.
Hara T; Hirayama F; Arima H; Yamaguchi Y; Uekama K
Chem Pharm Bull (Tokyo); 2006 Mar; 54(3):344-9. PubMed ID: 16508189
[TBL] [Abstract][Full Text] [Related]
17. Improved Aqueous Solubility and Antihypercholesterolemic Activity of Ezetimibe on Formulating with Hydroxypropyl-β-Cyclodextrin and Hydrophilic Auxiliary Substances.
Srivalli KM; Mishra B
AAPS PharmSciTech; 2016 Apr; 17(2):272-83. PubMed ID: 26077622
[TBL] [Abstract][Full Text] [Related]
18. Elucidation of the orientation of selected drugs with 2-hydroxylpropyl-β-cyclodextrin using 2D-NMR spectroscopy and molecular modeling.
Adhikari S; Daftardar S; Fratev F; Rivera M; Sirimulla S; Alexander K; Boddu SHS
Int J Pharm; 2018 Jul; 545(1-2):357-365. PubMed ID: 29747001
[TBL] [Abstract][Full Text] [Related]
19. Complexation with tolbutamide modifies the physicochemical and tableting properties of hydroxypropyl-beta-cyclodextrin.
Suihko E; Korhonen O; Järvinen T; Ketolainen J; Jarho P; Laine E; Paronen P
Int J Pharm; 2001 Mar; 215(1-2):137-45. PubMed ID: 11250099
[TBL] [Abstract][Full Text] [Related]
20. Improvement of dissolution and bioavailability of nitrendipine by inclusion in hydroxypropyl-beta-cyclodextrin.
Choi HG; Kim DD; Jun HW; Yoo BK; Yong CS
Drug Dev Ind Pharm; 2003 Nov; 29(10):1085-94. PubMed ID: 14677769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
